Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer
JCO Oncology Practice · 2023-05 · 19 (5) · e773-e783
DOI: 10.1200/op.22.00638 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2023-05. Verfasst von Daniel H Kwon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: COVID-19, Telemedicine, Prostatic Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Themen: Digitalisierung in der Pflege
Abstract (Originalsprache)
PURPOSE: Germline testing for men with prostate cancer (PCa) poses numerous implementation barriers. Alternative models of care delivery are emerging, but implementation outcomes are understudied. We evaluated implementation outcomes of a hybrid oncologist– and genetic counselor–delivered model called the genetic testing station (GTS) created to streamline testing and increase access. METHODS: A prospective, single-institution, cohort study of men with PCa referred to the GTS from October 14, 2019, to October 14, 2021, was conducted. Using the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework, we described patients referred to GTS (Reach), the association of GTS with germline testing completion rates within 60 days of a new oncology appointment in a pre- versus post-GTS multivariable logistic regression (Effectiveness), Adoption, Implementation, and Maintenance. Because GTS transitioned from an on-site to remote service during the COVID-19 pandemic, we also compared outcomes for embedded versus remote GTS. RESULTS: Overall, 713 patients were referred to and eligible for GTS, and 592 (83%) patients completed germline testing. Seventy-six (13%) patients had ≥ 1 pathogenic variant. Post-GTS was independently associated with higher odds of completing testing within 60 days than pre-GTS (odds ratio, 8.97; 95% CI, 2.71 to 29.75; P < .001). Black race was independently associated with lower odds of testing completion compared with White race (odds ratio, 0.35; 95% CI, 0.13 to 0.96; P = .042). There was no difference in test completion rates or patient-reported decisional conflict for embedded versus remote GTS. GTS has been adopted by 31 oncology providers across four clinics, and implementation fidelity was high with low patient loss to follow-up, but staffing costs are a sustainability concern. CONCLUSION: GTS is a feasible, effective model for high-volume germline testing in men with PCa, both in person and using telehealth. GTS does not eliminate racial disparities in germline testing access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, University of California San Francisco, San Francisco, CA.
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
- Cancer Genetics and Prevention Program, University of California San Francisco, San Francisco, CA.
ORCID-Profile: Daniel H Kwon, Barry Tong, Hala T Borno, Delaire Fattah, Rahul R Aggarwal, Eric J Small
Zitieren
APA
Kwon, D. H., Gordon, K. M., Tong, B., Borno, H. T., Beigh, M., Fattah, D., Schleicher, A., Aggarwal, R. R., Blanco, A. M., Small, E. J., & Dhawan, M. (2023). Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. JCO Oncology Practice, 19(5), e773-e783. https://doi.org/10.1200/op.22.00638
Vancouver
Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, et al. Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. JCO Oncology Practice. 2023;19(5):e773-e783. doi:10.1200/op.22.00638
BibTeX
@article{Kwon2023,
author = {Kwon, Daniel H and Gordon, Kelly M and Tong, Barry and Borno, Hala T and Beigh, Makenna and Fattah, Delaire and Schleicher, Alexandra and Aggarwal, Rahul R and Blanco, Amie M and Small, Eric J and Dhawan, Mallika},
title = {Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer},
journal = {JCO Oncology Practice},
year = {2023},
volume = {19},
number = {5},
pages = {e773--e783},
doi = {10.1200/op.22.00638}
}
EUVIMED